Observational studyBlood advances2026

Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen.

David Jacob Hermel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.